Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma

PURPOSE: Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs). However, the optimal dose is unknown. In this multicenter phase II and biomarker study, we eval...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Plotkin, Scott R., Duda, Dan G., Muzikansky, Alona, Allen, Jeffrey, Blakeley, Jaishri, Rosser, Tena, Campian, Jian L., Clapp, D. Wade, Fisher, Michael J., Tonsgard, James, Ullrich, Nicole, Thomas, Coretta, Cutter, Gary, Korf, Bruce, Packer, Roger, Karajannis, Matthias A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2019
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098833/
https://ncbi.nlm.nih.gov/pubmed/31626572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01367
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia